SecBot SecBot

SGP drug pipeline

SpyGlass Pharma, Inc. · 1 rated drug
$32.88
−1.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketPhase 3 trials are enrolling now; topline data expected in 2027. If successful, a 505(b)(2) NDA submission would follow, with potential FDA approval possibly in 2028-2029.

Bimatoprost Drug Pad-IOL System bimatoprost Updated Oct 24

What to watch

Watch for Phase 3 topline readout (expected in 2027, no precise date yet) as the defining binary catalyst. The FIH 4-year data (Oct 2026) de-risks Phase 3 replication risk somewhat, but Phase 3 results will determine whether the 505(b)(2) NDA submission proceeds. Also monitor FDA alignment updates and any accelerated enrollment announcements.

Bull case
  • 4-year FIH data (Oct 2026) showed 86% of patients off all topical glaucoma drops with no product-related adverse events, strong durability and safety signal.
  • Massive institutional accumulation in Q2 2026: BlackRock doubled (+392%), Vanguard doubled (+1,960%), Barclays doubled (+1,478%), and multiple others added or doubled positions.
  • Analyst consensus is strong-buy (5 strong buy, 4 buy, 1 hold) with a mean price target of $44 vs ~$28.50 current, implying ~54% upside.
Bear case
  • Phase 3 may fail to replicate Phase 1/2 results, the 4-year FIH data (N=21 evaluable) is a small sample and may not generalize to the broader Phase 3 population.
  • Cash burn is accelerating (net loss $39.9M in 2025 vs $29.2M in 2024), and while $251M runway runs through 2028, any Phase 3 delays would increase dilution risk.
  • Competition from existing glaucoma MIGS devices (iStent, Hydrus) and AbbVie's Durysta bimatoprost implant could limit commercial adoption even if approved.